These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33835207)

  • 1. Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients.
    Koning R; Bastard P; Casanova JL; Brouwer MC; van de Beek D;
    Intensive Care Med; 2021 Jun; 47(6):704-706. PubMed ID: 33835207
    [No Abstract]   [Full Text] [Related]  

  • 2. Autoantibodies against type I interferons in COVID-19 infection: A systematic review and meta-analysis.
    Wang X; Tang Q; Li H; Jiang H; Xu J; Bergquist R; Qin Z
    Int J Infect Dis; 2023 May; 130():147-152. PubMed ID: 36907547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interfering with Interferons: A Critical Mechanism for Critical COVID-19 Pneumonia.
    Su HC; Jing H; Zhang Y; Casanova JL
    Annu Rev Immunol; 2023 Apr; 41():561-585. PubMed ID: 37126418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type 1 interferons as a potential treatment against COVID-19.
    Sallard E; Lescure FX; Yazdanpanah Y; Mentre F; Peiffer-Smadja N
    Antiviral Res; 2020 Jun; 178():104791. PubMed ID: 32275914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Life-Threatening COVID-19: Defective Interferons Unleash Excessive Inflammation.
    Zhang Q; Bastard P; Bolze A; Jouanguy E; Zhang SY; ; Cobat A; Notarangelo LD; Su HC; Abel L; Casanova JL
    Med; 2020 Dec; 1(1):14-20. PubMed ID: 33363283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoantibodies Neutralizing Type I Interferons in 20% of COVID-19 Deaths in a French Hospital.
    Chauvineau-Grenier A; Bastard P; Servajean A; Gervais A; Rosain J; Jouanguy E; Cobat A; Casanova JL; Rossi B
    J Clin Immunol; 2022 Apr; 42(3):459-470. PubMed ID: 35083626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune response in SARS-CoV-2 infection: the role of interferons type I and type III.
    Portela Sousa C; Brites C
    Braz J Infect Dis; 2020; 24(5):428-433. PubMed ID: 32866437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon deficiency can lead to severe COVID.
    Meffre E; Iwasaki A
    Nature; 2020 Nov; 587(7834):374-376. PubMed ID: 33139913
    [No Abstract]   [Full Text] [Related]  

  • 9. Auto-antibodies against type I IFNs are associated with severe COVID-19 pneumonia.
    Zhou W; Wang W
    Signal Transduct Target Ther; 2021 Feb; 6(1):96. PubMed ID: 33637681
    [No Abstract]   [Full Text] [Related]  

  • 10. Plasmacytoid dendritic cells and type I interferons in flares of systemic lupus erythematosus triggered by COVID-19.
    Nasser N; Kurban M; Abbas O
    Rheumatol Int; 2021 May; 41(5):1019-1020. PubMed ID: 33666725
    [No Abstract]   [Full Text] [Related]  

  • 11. Roles of Type I and III Interferons in COVID-19.
    Choi H; Shin EC
    Yonsei Med J; 2021 May; 62(5):381-390. PubMed ID: 33908208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding immunopathological fallout of human coronavirus infections including COVID-19: Will they cross the path of rheumatologists?
    Kabeerdoss J; Danda D
    Int J Rheum Dis; 2020 Aug; 23(8):998-1008. PubMed ID: 32779341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A role for retinoids in the treatment of COVID-19?
    Trasino SE
    Clin Exp Pharmacol Physiol; 2020 Oct; 47(10):1765-1767. PubMed ID: 32459003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome.
    Devaux CA; Rolain JM; Raoult D
    J Microbiol Immunol Infect; 2020 Jun; 53(3):425-435. PubMed ID: 32414646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased type III interferons and NK cell functions in SARS-CoV-2-infected children.
    Jeong SD; Lee H; Chang JY; Lee SY; Choi JE; Yang E; Jeong HW; Choi JP; Han MS; Shin EC
    Signal Transduct Target Ther; 2023 Feb; 8(1):54. PubMed ID: 36737427
    [No Abstract]   [Full Text] [Related]  

  • 16. [COVID-toes, a cutaneous sign of innate resistance to SARS-CoV-2].
    Yatim A; Gilliet M
    Rev Med Suisse; 2021 Mar; 17(732):646-652. PubMed ID: 33793103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammation Triggered by SARS-CoV-2 and ACE2 Augment Drives Multiple Organ Failure of Severe COVID-19: Molecular Mechanisms and Implications.
    Iwasaki M; Saito J; Zhao H; Sakamoto A; Hirota K; Ma D
    Inflammation; 2021 Feb; 44(1):13-34. PubMed ID: 33029758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasmacytoid dendritic cell and type I interferons as possible explanation for clearance of longstanding warts during COVID-19 in a transplant patient, reply to Erkayman et al.
    Saadeh D; Kurban M; Abbas O
    Transpl Infect Dis; 2021 Aug; 23(4):e13585. PubMed ID: 33590633
    [No Abstract]   [Full Text] [Related]  

  • 19. Multiple organ dysfunction in SARS-CoV-2: MODS-CoV-2.
    Robba C; Battaglini D; Pelosi P; Rocco PRM
    Expert Rev Respir Med; 2020 Sep; 14(9):865-868. PubMed ID: 32567404
    [No Abstract]   [Full Text] [Related]  

  • 20. Comment on 'Vitiligo in a COVID-19-vaccinated patient with ulcerative colitis: coincidence?': Type I interferons as possible link between COVID-19 vaccine and vitiligo.
    Abdullah L; Awada B; Kurban M; Abbas O
    Clin Exp Dermatol; 2022 Feb; 47(2):436-437. PubMed ID: 34498300
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.